Clinical utility of NGS diagnosis and disease stratification in a multiethnic primary ciliary dyskinesia cohort

Author:

Fassad Mahmoud R.ORCID,Patel Mitali P.,Shoemark Amelia,Cullup Thomas,Hayward Jane,Dixon Mellisa,Rogers Andrew V.,Ollosson Sarah,Jackson Claire,Goggin Patricia,Hirst Robert A.,Rutman Andrew,Thompson James,Jenkins Lucy,Aurora Paul,Moya Eduardo,Chetcuti Philip,O'Callaghan Chris,Morris-Rosendahl Deborah J,Watson Christopher M.ORCID,Wilson Robert,Carr Siobhan,Walker Woolf,Pitno Andreia,Lopes Susana,Morsy Heba,Shoman Walaa,Pereira Luisa,Constant Carolina,Loebinger Michael R.,Chung Eddie M.K.,Kenia Priti,Rumman Nisreen,Fasseeh Nader,Lucas Jane S.,Hogg Claire,Mitchison Hannah M.ORCID

Abstract

BackgroundPrimary ciliary dyskinesia (PCD), a genetically heterogeneous condition enriched in some consanguineous populations, results from recessive mutations affecting cilia biogenesis and motility. Currently, diagnosis requires multiple expert tests.MethodsThe diagnostic utility of multigene panel next-generation sequencing (NGS) was evaluated in 161 unrelated families from multiple population ancestries.ResultsMost (82%) families had affected individuals with biallelic or hemizygous (75%) or single (7%) pathogenic causal alleles in known PCD genes. Loss-of-function alleles dominate (73% frameshift, stop-gain, splice site), most (58%) being homozygous, even in non-consanguineous families. Although 57% (88) of the total 155 diagnostic disease variants were novel, recurrent mutations and mutated genes were detected. These differed markedly between white European (52% of families carry DNAH5 or DNAH11 mutations), Arab (42% of families carry CCDC39 or CCDC40 mutations) and South Asian (single LRRC6 or CCDC103 mutations carried in 36% of families) patients, revealing a striking genetic stratification according to population of origin in PCD. Genetics facilitated successful diagnosis of 81% of families with normal or inconclusive ultrastructure and 67% missing prior ultrastructure results.ConclusionsThis study shows the added value of high-throughput targeted NGS in expediting PCD diagnosis. Therefore, there is potential significant patient benefit in wider and/or earlier implementation of genetic screening.

Funder

NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London

NIHR Southampton Respiratory Biomedical Research Unit

Ministry of Higher Education in Egypt

British Council Newton-Mosharafa Fund

NIHR Wellcome Trust Clinical Research Facility

AAIR Charity

COST Action BEAT-PCD: Better Evidence to Advance Therapeutic options for PCD network

Great Ormond Street Children’s Charity

Action Medical Research

Publisher

BMJ

Subject

Genetics (clinical),Genetics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3